After NDA Investment For OTC Switch, Success Swings On More Spending For Advertising

 
• By Malcolm Spicer

Switch consultant Susan Levy suggests drug firms temper enthusiasm for Rx-to-OTC switches with considering the costs NDAs generate and the histories of switches that haven’t been successes.

Shopping trolley with pills and medicine

More from Rx-to-OTC Switch

More from Health